Directions in Oncology Pharmacy® is getting to know oncology pharmacy professionals through a series of interviews. In this issue, we talk to David DeRemer, PharmD, BCOP, FCCP, FHOPA, president of the Hematology/Oncology Pharmacy Association (HOPA) Board of Directors, whose term ends this month.
As the most accessible member of the health care team, the pharmacist
can provide patients with cancer with the information and support necessary
to get through what could be the most challenging time in their lives.
Understanding breast cancer and which patients may be more vulnerable to long-term treatment effects and which patients may benefit most, can help oncologists design the best personalized neoadjuvant and adjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy.
In a Pharmacy Times® Peer Exchange video series, experts discussed the current landscape and management of relapsed or refractory multiple myeloma (RRMM), including the latest data and potential treatment strategies on the horizon.